HBeAg-negative hepatitis B is a form of chronic hepatitis B infection where the virus is able to reproduce without the "e" antigen protein. Around 40% of adults with chronic hepatitis B have this form, which can be more difficult to treat. Doctors recommend treatment for patients with HBeAg-negative hepatitis B if their viral load exceeds 2,000 IU/mL, even if liver enzymes are normal. Antiviral drugs entecavir and tenofovir are most effective in lowering viral load and improving liver damage for those never treated for hepatitis B.
HBeAg-negative hepatitis B is a form of chronic hepatitis B infection where the virus is able to reproduce without the "e" antigen protein. Around 40% of adults with chronic hepatitis B have this form, which can be more difficult to treat. Doctors recommend treatment for patients with HBeAg-negative hepatitis B if their viral load exceeds 2,000 IU/mL, even if liver enzymes are normal. Antiviral drugs entecavir and tenofovir are most effective in lowering viral load and improving liver damage for those never treated for hepatitis B.
HBeAg-negative hepatitis B is a form of chronic hepatitis B infection where the virus is able to reproduce without the "e" antigen protein. Around 40% of adults with chronic hepatitis B have this form, which can be more difficult to treat. Doctors recommend treatment for patients with HBeAg-negative hepatitis B if their viral load exceeds 2,000 IU/mL, even if liver enzymes are normal. Antiviral drugs entecavir and tenofovir are most effective in lowering viral load and improving liver damage for those never treated for hepatitis B.
HBeAg-negative hepatitis B is a form of chronic hepatitis B infection where the virus is able to reproduce without the "e" antigen protein. Around 40% of adults with chronic hepatitis B have this form, which can be more difficult to treat. Doctors recommend treatment for patients with HBeAg-negative hepatitis B if their viral load exceeds 2,000 IU/mL, even if liver enzymes are normal. Antiviral drugs entecavir and tenofovir are most effective in lowering viral load and improving liver damage for those never treated for hepatitis B.
Normally, the hepatitis B virus or HBeAg antigens. But some
(HBV) needs three proteins (also HBV, with certain mutations, are called antigens) in order to man- able to reproduce without the “e” ufacture more HBV. These are antigen. This is called HBeAg called the core, surface, and “e” negative hepatitis B.
If you test positive for the “e” antibody, but
continue to have elevated ALT and viral load (HBV DNA), you may have HBeAg-negative hepatitis B.
Some researchers estimate that about 40% of adults with chronic
hepatitis B have HBeAg-negative hepatitis B. This infection can be harder to treat. Doctors recommend treatment for HBeAg- negative patients if their viral load (HBV DNA) exceeds 2,000 IU/ mL, even if their alanine aminotransferases (ALT) are normal.
If you have never been treated for hepatitis B, research shows
that the antivirals entecavir (Baraclude) and tenofovir (Viread) appear to be most effective in lowering viral load (in about 90% of cases) and stopping liver damage (more than 75% achieve normal ALTs) but only while you take the antiviral medication, which comes in pill form.
Pegylated interferon, which is administered in a weekly injection
for 48 weeks or longer, also appears to be only slightly effective in lowering viral load (in 19% of cases). About 59% reduced their liver damage and achieved normal ALT.
People who have HBeAg-negative hepatitis
B could have a lab test result that shows: • The surface antigen (HBsAg) • The antibody to the “e” (HBeAg) antigen • A moderate (2,000-20,000 IU/mL) to high viral load (HBV DNA) • And, possibly, elevated ALT levels. VERSION 4.1 • November 2013 Alan Franciscus / Christine Kukka
Identification of Potentially Pathogenic Bacteria From Tilapia (Oreochromis Niloticus) and Channel Catfish (Clarias Batrachus) Culture in Samarinda, East Kalimantan, Indonesia